Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
⏸️ Best ASX Shares
Top ASX stock picks for May
Share Fallers
Why Kogan, Northern Star, Paradigm, & Wagners shares tumbled lower today
Share Market News
Where does the Paradigm Biopharmaceuticals share price go from here?
Share Gainers
Why this ASX300 healthcare share price is up 414% in the last year
Share Gainers
Over 610% higher in 12 months: The Paradigm share price still has plenty of growth ahead
⏸️ Best ASX Shares
Top ASX Stock Picks for April
Share Gainers
These small cap ASX shares are surging higher today
Share Gainers
Why the Paradigm Biopharmaceuticals share price rocketed 63% higher today
52-Week Highs
Is it too late to buy these market beating ASX shares?
Share Gainers
Why the Paradigm Biopharmaceuticals share price has surged 11% higher
Share Gainers
These 3 ASX small cap shares are ending the week on a high
Share Fallers
Why these 4 ASX shares are sinking lower today
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
